Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

The effect of therapeutic potential and safety of bone marrow-derived against adipose-derived mesenchymal stem cells in aged mice associated with septic arthritis.

Khalid Ahmed AM., Khalaf Ali M., Kh Alani B.

Animal Study with a reported sample of 9 on Cartilage Damage, published in PLoS One (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
PLoS One (2025)
Country
United States
Reported sample size
9
Source database
PubMed
PMID
41296765
PMCID
PMC12654889
DOI
10.1371/journal.pone.0335011
Citations
1

Abstract (original English)

Mesenchymal stem cells (MSCs) show potential for treating septic arthritis in aged populations, but their efficacy and safety in aged patients remain unclear. The objective of this study is to evaluate the therapeutic potential and safety profiles of bone marrow-derived MSCs (BM-MSCs) and adipose-derived MSCs (AD-MSCs) in aged murine model of septic arthritis. MSCs were isolated, characterized, and labeled for in vivo tracking. The experiment consisted of a total of 36 mice, which included 9 subgroups with four replicates per treated group: control group, treated groups (BM-MSC1, BM-MSC2, AD-MSC1, and AD-MSC2), and untreated groups (Un-BM1, Un-BM2, Un-AD1, and Un-AD2). The treated groups received MSC therapy following the induction of septic arthritis via intra-articular injection of Staphylococcus aureus. The results showed that BM-MSC1 significantly performed higher than AD-MSCs in reducing inflammation, promoting cartilage repair, and modulating immune responses. BM-MSC1 showed significant upregulation of regenerative markers such as interleukin-10 (IL-10) and collagen type II alpha 1 chain (COL2A1) and downregulation of pro-inflammatory markers such as tumor necrosis factor-alpha (TNF-a) and matrix metalloproteinase-13 (MMP-13). Imaging confirmed superior retention, engraftment, and host tissue interaction for BM-MSCs. AD-MSCs showed slightly lower efficacy and safety, high

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMesenchymal Stem CellsArthritis, InfectiousMesenchymal Stem Cell TransplantationMiceAdipose TissueBone Marrow CellsMaleAgingDisease Models, Animal

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research